<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628259</url>
  </required_header>
  <id_info>
    <org_study_id>EKILINCISLEYEN</org_study_id>
    <nct_id>NCT05628259</nct_id>
  </id_info>
  <brief_title>The Effect of Motivational Interviewing With Video Call in Individuals With Type 2 Diabetes:RCT</brief_title>
  <official_title>The Effect of Motivational Interviewing With Video Call on Diabetes Self-Efficacy, Diabetes Self-Management and Metabolic Control Parameters in Individuals With Type 2 Diabetes: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pamukkale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bakırkoy Dr. Sadi Konuk Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pamukkale University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be carried out to examine the effect of motivational interviewing applied by&#xD;
      video call on diabetes self-efficacy, diabetes self-management and metabolic control&#xD;
      parameters (HbA1c%, BMI, fasting glucose, cholesterol, blood pressure, waist circumference)&#xD;
      in individuals with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2, 2023</start_date>
  <completion_date type="Anticipated">July 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a parallel group randomized controlled study.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single blinding was provided that included inclusion criteria and agreement to participate in the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Diabetes Self-Efficacy Scale</measure>
    <time_frame>Change from Baseline diabetes self-efficacy at 6 months</time_frame>
    <description>The change in diabetes self efficacy of individuals with Type 2 diabetes at 3rd month and 6 rd month with the Diabetes Self-Efficacy Scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetes Self-Management Scale</measure>
    <time_frame>Change from Baseline diabetes self-management at 6 months</time_frame>
    <description>This scale was used to measure the behavioral component of individuals in the IMB model. The validity and reliability study of the Turkish Diabetes Self-Management Perception Scale was conducted by Eroğlu and Sabuncu (2018). The scale consists of 16 items and 4 sub-dimensions and is a 4-point Likert type. Glucose Management sub-dimension: Items 4, 6, 10, 12 (items 4 and 12 are about drug use, items 1, 6 and 10 are about blood glucose monitoring). Diet Control sub-dimension: Items 2, 5, 9, 13. Physical Activity sub-dimension: Items 8, 11, 15. Use of Health Services sub-dimension: It consists of 3, 7, 14, and 16 items. The DMS scale consists of 16 items, 7 of which are straight and 9 of which are reversed. The scores of the items numbered &quot;5, 7, 10, 11, 12, 13, 14, 15 and 16&quot; in the scale are calculated by reversing them. Diabetes self-management increases as the score gets closer to 10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c%</measure>
    <time_frame>Change from Baseline HbA1c% at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Change from Baseline Body Mass Index at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>Change from Baseline Fasting glucose at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>Change from Baseline Cholesterol at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>Change from Baseline waist circumference at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Change from Baseline blood pressure % at 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Self Efficacy</condition>
  <condition>Self Management</condition>
  <condition>Video Call</condition>
  <condition>HbA1c</condition>
  <condition>BMI</condition>
  <condition>Blood Pressure</condition>
  <condition>Fasting Glucose</condition>
  <condition>Cholesterol Deposition</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group received routine nursing care in the internal diseases policlinic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Interviewing with WhatsApp video call</intervention_name>
    <description>The individuals in the intervention group will be given a motivational interview with a WhatsApp video call for 3 months. Motivational interview will be applied every two weeks, 6 times in total.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Those between the ages of 30-64&#xD;
&#xD;
          -  Receiving insulin therapy&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes at least six months ago&#xD;
&#xD;
          -  BMI value of 25 and above&#xD;
&#xD;
          -  HbA1c of 8 and above (poor control)&#xD;
&#xD;
          -  At least primary school graduate and can speak Turkish&#xD;
&#xD;
          -  No communication barrier (speech, vision or hearing problem)&#xD;
&#xD;
          -  Having a smart phone and internet access&#xD;
&#xD;
          -  Individuals who agree to participate in the research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Communication disability (speech, vision or hearing problem)&#xD;
&#xD;
          -  Those with neuropathy at a level that prevents them from doing their daily physical&#xD;
             activities&#xD;
&#xD;
          -  Diagnosed with kidney failure (acute or chronic)&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Those with a diagnosis of cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eda Kılınç İşleyen</name>
      <address>
        <city>Pamukkale</city>
        <state>Denizli</state>
        <zip>(545)-561 96 83</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Eda Kılınç İşleyen, PhD, RN.</last_name>
      <phone>+905455619683</phone>
      <email>kilinc_edaa@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>İrem Nur ÖZDEMİR</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>İrem Nur ÖZDEMİR, PhD</last_name>
      <phone>+905076472107</phone>
      <email>iremozdemir92@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Şengül AYDIN YOLDEMİR</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Şengül AYDIN YOLDEMİR, PhD. MD.</last_name>
      <phone>+90(530)9383833</phone>
      <email>sengulaydinn@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 25, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2022</study_first_posted>
  <last_update_submitted>November 25, 2022</last_update_submitted>
  <last_update_submitted_qc>November 25, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pamukkale University</investigator_affiliation>
    <investigator_full_name>EDA KILINÇ İŞLEYEN</investigator_full_name>
    <investigator_title>Dr. Research Assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

